Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Bibliographic Details
Main Authors:	Madi, A, Fisher, D, Wilson, R H, Adams, R A, Meade, A M, Kenny, S L, Nichols, L L, Seymour, M T, Wasan, H, Kaplan, R, Maughan, T S
Format:	Online
Language:	English
Published:	Nature Publishing Group 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461171/

Similar Items

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
by: Adams, Richard A, et al.
Published: (2011)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
by: Maughan, Timothy S, et al.
Published: (2011)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
by: Lorenzen, S, et al.
Published: (2013)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
by: Aitini, Enrico, et al.
Published: (2012)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
by: Kim, Jung Han, et al.
Published: (2015)

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract
by: Graham, J. S., et al.
Published: (2016)

Oxaliplatin in practice.
by: Misset, J. L.
Published: (1998)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
by: Ferrarotto, Renata, et al.
Published: (2013)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
by: Buchler, Tomas, et al.
Published: (2014)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
by: Hoehler, T, et al.
Published: (2013)

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
by: O'Byrne, K. J., et al.
Published: (1998)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
by: Feliu, J, et al.
Published: (2014)

Ongoing and unsaid on oxaliplatin: the hope.
by: Cvitkovic, E.
Published: (1998)

Fatal Pneumonitis Induced by Oxaliplatin: Description of Three Cases
by: Pontes, L.B., et al.
Published: (2012)

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
by: Mammoliti, S., et al.
Published: (2011)

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study
by: Grenader, Tal, et al.
Published: (2016)

Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells
by: Mori, Ryutaro, et al.
Published: (2012)

The impact of chemosensory and food-related changes in patients with advanced oesophagogastric cancer treated with capecitabine and oxaliplatin: a qualitative study
by: de Vries, Yfke C., et al.
Published: (2016)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
by: Chen, Ming-Huang, et al.
Published: (2016)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
by: Boisen, Mogens K., et al.
Published: (2014)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
by: Hansen, Torben Frøstrup, et al.
Published: (2012)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
by: Dellas, Kathrin, et al.
Published: (2013)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
by: Liu, Yingmiao, et al.
Published: (2013)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
by: Liu, Ying, et al.
Published: (2013)

Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman
by: Gurzu, Simona, et al.
Published: (2013)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
by: Hwang, Seung Jae, et al.
Published: (2006)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
by: Wanghua Chen, et al.
Published: (2018-08-01)

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
by: Lee, Ha Yeon, et al.
Published: (2016)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
by: Kim, Seung Tae, et al.
Published: (2016)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mashhadi, Mohammad Ali, et al.
Published: (2016)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
by: Munemoto, Yoshinori, et al.
Published: (2015)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
by: Bazarbashi, Shouki, et al.
Published: (2015)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
by: Weickhardt, Andrew, et al.
Published: (2011)

Broad funding for oxaliplatin in Ontario (finally!)
by: Jonker, D., et al.
Published: (2007)

Management of oxaliplatin-induced peripheral neuropathy
by: Saif, M Wasif, et al.
Published: (2005)

TECHNOLOGICAL PARAMETERS OF PRODUCTION OF LIPOSOMES WITH OXALIPLATIN
by: O. V. Stadnichenko, et al.
Published: (2018-03-01)

Oxaliplatin-Induced Tonic-Clonic Seizures
by: Rahal, Ahmad K., et al.
Published: (2015)

Oxaliplatin Induced Digital Ischemia and Necrosis
by: Karabacak, Kubilay, et al.
Published: (2015)

A case of oxaliplatin-induced immune-mediated thrombocytopenia
by: Suh, Seong Eun, et al.
Published: (2014)